These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33563034)

  • 1. Safety and Effectiveness of an Accelerated Intravenous Iron Administration Protocol in Hospitalized Patients With Heart Failure.
    Eche IM; Owen KL; Eche IJ; Patel P; Sabe M
    J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):365-370. PubMed ID: 33563034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IV Sodium Ferric Gluconate Complex in Patients Hospitalized Due to Acute Decompensated Heart Failure and Iron Deficiency.
    Borreda I; Zukermann R; Epstein D; Marcusohn E
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484211055639. PubMed ID: 34994220
    [No Abstract]   [Full Text] [Related]  

  • 3. IV Sodium Ferric Gluconate Complex in Patients With Iron Deficiency Hospitalized due to Acute Heart Failure-Investigator Initiated, Randomized Controlled Trial.
    Marcusohn E; Borreda I; Hellman Y; Habib M; Bahouth F; Epstein D; Zukermann R
    J Cardiovasc Pharmacol; 2022 Aug; 80(2):194-196. PubMed ID: 35503997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction.
    Dashwood A; Vale C; Laher S; Chui F; Hay K; Wong YW
    J Clin Pharmacol; 2021 Apr; 61(4):515-521. PubMed ID: 33051909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (> or =250 mg) administration.
    Folkert VW; Michael B; Agarwal R; Coyne DW; Dahl N; Myirski P; Warnock DG;
    Am J Kidney Dis; 2003 Mar; 41(3):651-7. PubMed ID: 12612989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
    Michael B; Coyne DW; Fishbane S; Folkert V; Lynn R; Nissenson AR; Agarwal R; Eschbach JW; Fadem SZ; Trout JR; Strobos J; Warnock DG;
    Kidney Int; 2002 May; 61(5):1830-9. PubMed ID: 11967034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease.
    Panesar A; Agarwal R
    Am J Kidney Dis; 2002 Nov; 40(5):924-31. PubMed ID: 12407636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of an accelerated intravenous iron regimen in hospitalized patients with advanced heart failure and iron deficiency.
    Reed BN; Blair EA; Thudium EM; Waters SB; Sueta CA; Jensen BC; Rodgers JE
    Pharmacotherapy; 2015 Jan; 35(1):64-71. PubMed ID: 25556867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients.
    Coyne DW; Adkinson NF; Nissenson AR; Fishbane S; Agarwal R; Eschbach JW; Michael B; Folkert V; Batlle D; Trout JR; Dahl N; Myirski P; Strobos J; Warnock DG;
    Kidney Int; 2003 Jan; 63(1):217-24. PubMed ID: 12472786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
    Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
    Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ferric carboxymaltose in patients with heart failure and iron deficiency.
    Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
    N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status.
    Bhandari S; Allgar V; Lamplugh A; Macdougall I; Kalra PA
    BMC Nephrol; 2021 Mar; 22(1):115. PubMed ID: 33784968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial.
    Brautaset Englund KV; Østby CM; Rolid K; Gude E; Andreassen AK; Gullestad L; Broch K
    J Heart Lung Transplant; 2021 May; 40(5):359-367. PubMed ID: 33612360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study on secondary anemia in "frailty" patients treated with Ferric Sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate and selenomethionine: safety of treatment explored by HRV non-linear analysis as predictive factor of cardiovascular tolerability.
    Marchitto N; Curcio A; Iannarelli N; Petrucci A; Romano A; Pironti M; Paparello PT; Raimondi G
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7776-7783. PubMed ID: 32744704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex.
    Michael B; Fishbane S; Coyne DW; Agarwal R; Warnock DG
    Nat Clin Pract Nephrol; 2006 Feb; 2(2):92-100. PubMed ID: 16932400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety.
    Michael B; Coyne DW; Folkert VW; Dahl NV; Warnock DG;
    Nephrol Dial Transplant; 2004 Jun; 19(6):1576-80. PubMed ID: 15034152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
    Anirban G; Kohli HS; Jha V; Gupta KL; Sakhuja V
    Ren Fail; 2008; 30(6):629-38. PubMed ID: 18661414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous iron replacement with sodium ferric gluconate complex in sucrose for iron deficiency anemia in adults.
    Kane RC
    Curr Ther Res Clin Exp; 2003 Apr; 64(4):263-8. PubMed ID: 24944373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects.
    Seligman PA; Dahl NV; Strobos J; Kimko HC; Schleicher RB; Jones M; Ducharme MP
    Pharmacotherapy; 2004 May; 24(5):574-83. PubMed ID: 15162891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.